Byetta 5 mcg Pen

Regulated Product — Business License Required

B2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.

Product photography not yet supplied — this space will show official packaging imagery once provided by the business.

Product Overview

Byetta 5 mcg Pen contains exenatide, a GLP-1 receptor agonist delivered by pre-filled injection pen. It is prescribed for adults with type 2 diabetes mellitus to help lower blood glucose — supporting insulin release and reducing appetite — and to help reduce the risk of serious diabetes-related complications.

Active ingredient
Exenatide
Strength
5 mcg per dose
Dosage form
Solution for injection (pre-filled pen)
Therapeutic class
GLP-1 receptor agonist
Regulatory status
Prescription / regulated — confirmed per enquiry and destination market
Availability
Confirmed per enquiry

Product Information

The following description reflects information associated with exenatide and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.

Described Uses

  • Management of type 2 diabetes mellitus in adult patients
  • Described as lowering blood glucose and reducing appetite by supporting insulin production
  • Described as helping to reduce the risk of complications such as kidney damage and vision loss
Note: SDO Pharma has not independently verified the manufacturer’s efficacy claims for this product and makes no additional medical or clinical claims beyond what is described here. We do not claim FDA, UAE, EU, or other specific regulatory approval for this product unless independently verified. This is a prescription / regulated-status product; patient dispensing is the responsibility of the licensed business customer, not SDO Pharma.

Described Dosage & Administration

  • Given by subcutaneous injection, generally within 60 minutes before the morning and evening meals, per prescribing information
  • First administered by a doctor or nurse; the patient and caregiver are then trained to use the pen at home
  • Dose and duration are set by the prescriber; treatment should not be stopped without advice

Described Side Effects

Commonly described side effects include:

  • Nausea and vomiting
  • Diarrhoea
  • Low blood glucose (hypoglycaemia) when combined with insulin or a sulfonylurea

Any severe, persistent, or unexpected reaction requires prompt medical attention.

Precautions

  • Any problems with the pancreas or stomach, diabetic ketoacidosis, or severe dehydration should be disclosed to the prescriber
  • Driving and operating machinery should be avoided if symptoms of low blood sugar occur
  • Pregnancy or breastfeeding should be discussed with the prescriber
  • Full medical history should be shared with the prescriber

This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.

B2B, Import & Export

B2B, Import & Export Enquiries

SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.

We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.

Product Enquiry

Request Product Information

Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.

Frequently Asked Questions

Per its labelling, exenatide is a GLP-1 receptor agonist used in adults to lower blood glucose in type 2 diabetes mellitus. SDO Pharma has not independently verified these claims.

By subcutaneous injection from the pen, generally within 60 minutes before the morning and evening meals, after training by a healthcare professional.

Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.

Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.

Explore More

Related Product Categories

SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.

View Products & Services